These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28046099)

  • 1. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    Stahmeyer JT; Rossol S; Liersch S; Guerra I; Krauth C
    PLoS One; 2017; 12(1):e0169401. PubMed ID: 28046099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.
    Thokala P; Simpson EL; Tappenden P; Stevens JW; Dickinson K; Ryder S; Harrison P
    Pharmacoeconomics; 2016 Aug; 34(8):741-50. PubMed ID: 26892974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Ruggeri M; Rolli FR; Kondili LA; Drago C; De Solda F; Nappi C; Cicchetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):363-374. PubMed ID: 30351994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
    J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of treating hepatitis C in Seychelles.
    Adeline NJF; Geue C; Hermami MR
    Pan Afr Med J; 2019; 33():26. PubMed ID: 31384341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
    Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
    Front Public Health; 2021; 9():779215. PubMed ID: 34957030
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
    Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.